INTRODUCTION {#s1}
============

The worldwide annual incidence of head and neck squamous cell carcinoma (HNSCC) is approximately 740,000 cases, with approximately 300,000 deaths each year \[[@R1], [@R2]\]. This high incidence, mainly affecting the oral cavity, the pharynx and the larynx, is associated with low survival and high mortality rates.

Over the last 30 years, much has been learned regarding the role of chemotherapy, radiation therapy, and combined-modality treatment with chemoradiation (CRT) in the treatment of locally advanced head and neck cancer. For instance, taxanes have been proven to have significant single-agent activity, increasing interest in the incorporation of taxanes into induction regimens for the treatment of patients with locally advanced HNSCC \[[@R3]\].

The treatment of early stage HNSCC tumors is conducted preferably with surgery and radiation, with curative rates of approximately 80 to 90%. Conversely, the treatment of patients with locally advanced disease (stage III or IV) involves CRT or surgery followed by adjuvant radiotherapy/CRT. However, only 30-50% of patients with locally advanced disease survive more than five years, despite the advances in surgical techniques and the recognized benefits of CRT \[[@R4]--[@R6]\].

Furthermore, despite recent improvements in treatment approaches, the prognosis for HNSCC patients did not improve at the same pace as these advancements, and still, most of the cases are diagnosed in advanced stages of HNSCC. In this scenario, improvement in patient\'s survival requires both early detection \[[@R7]\] as well as the possibility of predicting, at the moment of diagnosis, which patients will benefit from a specific treatment. Tailoring the treatment is of great importance and may help in the management of treatment planning and follow-up, improving survival rates.

MicroRNAs (miRNAs) represent a class of non-coding RNAs acting as post-transcriptional gene expression regulators by inhibiting translation or destabilizing mRNAs. They are involved in the regulation and coordination of multiple cellular pathways and processes. MiRNAs are responsive to various cellular stressors and are key players in many diseases including cancer \[[@R8], [@R9]\]. Studies have shown that miRNAs may affect cancer development and the regulation of the immune/inflammation or cell death responses as well as may be used in early detection, diagnosis and prognosis of different diseases \[[@R10]\].

The aim of the present study was to evaluate if miRNAs are able to predict the response to an organ preservation protocol based on chemoradiation \[[@R3]\]. For this purpose, we assessed the global miRNA expression profile of HNSCC patients with locally advanced and unresectable tumors undergoing treatment. We looked for miRNAs differentially expressed in complete responders vs. non-responders, thus serving as markers to predict response.

RESULTS {#s2}
=======

Characteristics of the patients {#s2_1}
-------------------------------

The study population comprised a cohort of 71 patients with a confirmed diagnosis of squamous cell carcinoma of the oropharynx, larynx or hypopharynx and submitted to an organ preservation protocol in our institution from 2009 to 2011. The protocol is based on induction chemotherapy followed by concomitant chemoradiation; details of the treatment protocol have been previously published \[[@R3]\]. Patients were mainly males (95.8%), with an age range of 40-76 years (median of 56 years). Tobacco or alcohol consumption was reported by 80.3% and 38.0% of the patients, respectively. The primary tumor sites were located in the oropharynx (49.3%), larynx (39.4%) and hypopharynx (11.3%). Clinical stage (CS) classification was T2/T3 in 46 cases (64.8%) and T4 in 25 cases (35.2%), N0/N1 in 35 cases (49.3%) and N2/N3 in 36 cases (50.7%). Patients were grouped as 29 cases with CS III (40.8%) and 42 with CS IV (59.2%). Six cases were considered unresectable (8.5%). With regard to HPV status, 6 (18.2%) of the oropharynx tumors were considered HPV-positive. Only 1 patient with a larynx tumor (3.6%) and none of the patients with hypopharynx tumors presented with positive p16 immunoexpression.

miRNA microarrays expression ('screening set') {#s2_2}
----------------------------------------------

The miRNA expression profile for patients who underwent chemoradiation protocol was assessed in 15 samples ('screening set') by microarray. FFPE samples were divided into the following 2 groups: 8 FFPE samples from responder patients and 7 FFPE samples from non-responder patients, after chemoradiation. To evaluate differentially expressed miRNAs between the two groups, the rank product analysis was performed for p-value ≤ 0.001, in tandem with the rate of false positive predictions (pfp) ≤ 0.05.

The heatmap of the differentially expressed miRNAs with p-value ≤ 0.001 identified 7 miRNAs (hsa-miR-21, hsa-miR-923_v12.0, hsa-miR-766, hsa-miR-1274b, hsa-miR-720, hsa-miR-1308 and hsa-miR-494; Figure [1](#F1){ref-type="fig"}). Of the 7 significantly different miRNAs, 4 miRNAs (hsa-miR-21, hsa-miR-923_v12.0, hsa-miR-720 and hsa-miR-494) were selected for further validation in the 'validation set'.

![The hierarchical clustering image of 7 differentially expressed miRNAs (p≤0.001) in HNSCC when comparing groups of Complete Response (CR) versus Partial Response + Stable Disease + Tumor Progression (Non-CR)](oncotarget-08-9911-g001){#F1}

miRNAs RT-qPCR expression ('validation set') {#s2_3}
--------------------------------------------

The validation of microarray results was conducted by reverse transcription quantitative PCR (RT-qPCR). The data were normalized using the expression of SNORD48 (RNU48) and U6snRNA as endogenous references.

The miRNA expression was then validated in a different set of patients ('validation set'). The 'validation set' included 47 patients from the remaining cohort, who had finished the organ preservation protocol and were evaluated for treatment response. The expression levels of the four selected miRNAs (miR-21, miR-923, miR-720 and miR-494) were assessed.

When evaluating complete responders after chemoradiation (CRT) vs. non-responders (partial response or stable disease or tumor progression), only the results for miR-21 were validated: of all the patients who highly expressed miR-21, 70.8% did not have a complete response after chemoradiation, while 39.1% had a complete response (p=0.029) (Table [1](#T1){ref-type="table"}). Moreover, in a multivariate analysis, using a model adjusted for age, tumor site, p16 immunoexpression and tumor resectability, high expression of miR-21 remained as an independent predictor of poor response to the organ preservation protocol (OR=5.69; 95%CI 1.27-25.58; p=0.023), together with clinical stage IV (OR=5.05; 95%CI 1.22-20.88; p=0.025) (Table [2](#T2){ref-type="table"}).

###### Results from univariate analysis for organ preservation protocol response and microRNA expression (qPCR) for the 'validation set'

                       *Overall response after chemoradiation (CRT)*               
  -------------------- ----------------------------------------------- ----------- -----------
  **miR-21**                                                                       
   *Low expression*    14 (60.9)                                       7 (29.2)    **0.029**
   *High expression*   9 (39.1)                                        17 (70.8)   
  **miR-494**                                                                      
   *Low expression*    10 (43.5)                                       9 (37.5)    0.676
   *High expression*   13 (56.5)                                       15 (62.5)   
  **miR-720**                                                                      
   *Low expression*    12 (52.2)                                       10 (41.7)   0.471
   *High expression*   11 (47.8)                                       14 (58.3)   
  **miR-923**                                                                      
   *Low expression*    8 (34.8)                                        9 (37.5)    0.846
   *High expression*   15 (65.2)                                       15 (62.5)   

CR -- complete response; PR -- partial response; SD -- stable disease; TP -- tumor progression.

###### Logistic regression analysis for poor overall response to the organ preservation protocol (for the 'validation set' patients)

  Variable                 Adjusted OR\* (95% CI)   p-value
  ------------------------ ------------------------ -----------
  ***miR-21expression***                            
   *Low expression*        1 (ref.)                 **0.023**
   *High expression*       5.69 (1.27 -- 25.58)     
  ***Tumor Staging***                               
   *CS III*                1 (ref.)                 **0.025**
   *CS IV*                 5.05 (1.22 -- 20.88)     

\*Adjusted by age, tumor site, p16 immunoexpression and tumor resectability

Expression profile and clinical data associations {#s2_4}
-------------------------------------------------

The expression profile of the 4 selected miRNAs was analyzed considering the entire cohort (all patients with clinical information and samples analyzed for miRNAs by RTq-PCR) for potential associations with patients' clinical-pathological characteristics and survival analysis.

The analysis showed that the patients who were alcohol consumers had higher miR-21 expression than the patients who did not drink alcohol (p=0.009). Moreover, oropharynx patients had higher miR-720 expression when compared to larynx and hypopharynx patients (p=0.043) (Table [3](#T3){ref-type="table"}).

###### Results of univariate analysis of clinical, pathological and microRNA expression data of the patients (entire cohort) enrolled in the study

                               miR-21 Expression   miR-494 Expression   miR-720 Expression   miR-923 Expression                                                                                       
  ---------------------------- ------------------- -------------------- -------------------- -------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ---------
  ***Age***                                                                                                                                                                                           
   \< 60 years-old             21 (47.7)           23 (52.3)            0.736                19 (43.2)            25 (56.8)   0.311       19 (43.2)   25 (56.8)   0.188       23 (52.3)   21 (47.7)   0.522
   ≥ 60 years-old              14 (51.9)           13 (48.1)            15 (55.6)            12 (44.4)            16 (59.3)   11 (40.7)   12 (44.4)   15 (55.6)                                       
  ***Gender***                                                                                                                                                                                        
   Male                        33 (48.5)           35 (51.5)            0.614\*              32 (47.1)            36 (52.9)   0.604\*     34 (50.0)   34 (50.0)   1.000\*     33 (48.5)   35 (51.5)   0.614\*
   Female                      2 (66.7)            1 (33.3)             2 (66.7)             1 (33.3)             1 (33.3)    2 (66.7)    2 (66.7)    1 (33.3)                                        
  ***Tobacco consumption***                                                                                                                                                                           
   Yes                         26 (45.6)           31 (54.4)            0.211                27 (47.4)            30 (52.6)   0.860       30 (52.6)   27 (47.4)   0.257       27 (47.4)   30 (52.6)   0.512
   No                          9 (64.3)            5 (35.7)             7 (50.0)             7 (50.0)             5 (35.7)    9 (64.3)    8 (57.1)    6 (42.9)                                        
  ***Alcohol consumption***                                                                                                                                                                           
   Yes                         8 (29.6)            19 (70.4)            **0.009**            11 (40.7)            16 (53.3)   0.345       13 (48.1)   14 (51.9)   0.880       11 (40.7)   16 (53.3)   0.259
   No                          27 (61.4)           17 (38.6)            23 (52.3)            21 (47.7)            22 (50.0)   22 (50.0)   24 (54.5)   20 (45.5)                                       
  ***Tumor site***                                                                                                                                                                                    
   Oropharynx                  17 (48.6)           18 (51.4)            0.904                13 (37.1)            22 (62.9)   0.074       13 (37.1)   22 (62.9)   **0.043**   15 (42.9)   20 (57.1)   0.285
   Larynx/Hypopharynx          18 (50.0)           18 (50.0)            21 (58.3)            15 (41.7)            22 (61.1)   14 (38.9)   20 (55.6)   16 (44.4)                                       
  ***Ressecability***                                                                                                                                                                                 
   Resectable                  32 (49.2)           33 (50.8)            1.000\*              31 (47.7)            34 (52.3)   1.000\*     34 (52.3)   31 (47.7)   0.199\*     31 (47.7)   34 (52.3)   0.429\*
   Unresectable                3 (50.0)            3 (50.0)             3 (50.0)             3 (50.0)             1 (16.7)    5 (83.3)    4 (66.7)    2 (33.3)                                        
  ***T Stage***                                                                                                                                                                                       
   T2 and T3                   24 (54.2)           22 (47.8)            0.511                21 (45.7)            25 (54.3)   0.609       26 (56.5)   20 (43.5)   0.099       23 (50.0)   23 (50.0)   0.872
   T4                          11 (44.0)           14 (56.0)            13 (52.0)            12 (48.0)            9 (36.0)    16 (64.0)   12 (48.0)   13 (52.0)                                       
  ***N Stage***                                                                                                                                                                                       
   N0 and N1                   16 (45.7)           19 (54.3)            0.552                15 (42.9)            20 (57.1)   0.403       20 (57.1)   15 (42.9)   0.192       15 (42.9)   20 (57.1)   0.285
   N2 and N3                   19 (52.8)           17 (47.2)            19 (52.8)            17 (47.2)            15 (41.7)   21 (58.3)   20 (55.6)   16 (44.4)                                       
  ***Tumor Staging***                                                                                                                                                                                 
   CS III                      14 (48.3)           15 (51.7)            0.886                10 (34.5)            19 (65.5)   0.060       18 (62.1)   11 (37.9)   0.074       12 (41.4)   17 (58.6)   0.268
   CS IV                       21 (50.0)           21 (50.0)            24 (57.1)            18 (42.9)            17 (40.5)   25 (59.5)   23 (54.8)   19 (45.2)                                       
  ***p16 Immunoexpression***                                                                                                                                                                          
   Positive                    2 (28.6)            5 (71.4)             0.431\*              3 (42.9)             4 (57.1)    1.000\*     3 (42.9)    4 (57.1)    0.710\*     4 (57.1)    3 (42.9)    0.710\*
   Negative                    31 (50.0)           31 (50.0)            30 (48.4)            32 (51.6)            32 (51.6)   30 (48.4)   30 (48.4)   32 (51.6)                                       

CS -- clinical stage

\*Fisher's exact test

The 5-year disease-free survival (DFS) rate for the cohort was 54.5%, and the 5-year overall survival rate was 40.0%. None of the miRNAs validated in the study were significantly associated with disease-free survival or overall survival in the univariate Kaplan-Meier analysis (Table [4](#T4){ref-type="table"}). However, the 5-year overall survival rate for patients with a low expression of miR-21 was 50.5%, compared to a 29.4% overall survival rate for those with a high expression of this miRNA (p=0.056) (Figure [2](#F2){ref-type="fig"}). Furthermore, a multivariate Cox regression analysis, in a model adjusted for age, tumor site, tumor resectability, and 'screening' vs. 'validation' sets, indicated that miR-21 (HR=2.05; 95%CI 1.05-4.02; p=0.036) and clinical stage IV (HR=3.17; 95%CI 1.49-6.77; p=0.003) are independent prognostic factors (Table [5](#T5){ref-type="table"}).

###### Results of univariate Kaplan-Meier survival analysis regarding disease-free and overall survival for the entire cohort

                     5-year Disease-Free Survival (%)   p-value(log-rank)   5-year Overall Survival (%)   p-value (log-rank)
  ------------------ ---------------------------------- ------------------- ----------------------------- --------------------
  ***miR-21***                                                                                            
   Low expression    62.7                               0.451               50.5                          0.056
   High expression   43.7                               29.4                                              
  ***miR-494***                                                                                           
   Low expression    59.5                               0.527               43.3                          0.683
   High expression   50.3                               37.9                                              
  ***miR-720***                                                                                           
   Low expression    64.4                               0.282               45.7                          0.376
   High expression   45.5                               35.0                                              
  ***miR-923***                                                                                           
   Low expression    50.8                               0.567               39.3                          0.489
   High expression   58.0                               41.3                                              

![A 5-year overall survival rate according to miR-21 expression level in HNSCC samples](oncotarget-08-9911-g002){#F2}

###### Multivariate Cox regression analysis for overall survival (entire cohort of patients)

  Characteristic           Adjusted HR\* (95% CI)   p-value
  ------------------------ ------------------------ -----------
  ***miR-21expression***                            
   *Low expression*        1 (ref.)                 **0.036**
   *High expression*       2.05 (1.05 -- 4.02)      
  ***Tumor Staging***                               
   *CS III*                1 (ref.)                 **0.003**
   *CS IV*                 3.17 (1.49 -- 6.77)      

\* Adjusted by age, tumor site, tumor resectability, and set 'screening vs. validation'

DISCUSSION {#s3}
==========

There is still uncertainty concerning the functional role of most miRNAs, as one miRNA may target multiple mRNAs and one mRNA can be regulated by a number of different miRNAs \[[@R7], [@R9], [@R11]--[@R13]\].

Evidence suggests that miRNAs may both prove to be useful as diagnostic and prognostic markers as well as highlight the competency for targeted therapies \[[@R7], [@R9], [@R11], [@R12], [@R14]\]. Microarray and RT-qPCR have been widely applied for the identification of miRNAs that are differentially expressed in HNSCC. However, it has been challenging to characterize a consistent miRNA signature. Therefore, assessing global miRNA expression and its association with tumor characteristics could represent a promising approach to improve disease diagnosis and therapeutic protocols and, thus, increase patient survival.

MiR-21 is regarded as a key oncogenic factor and its function in the progression of cancer has been widely investigated in many types of cancers \[[@R15], [@R16]\]. In many tumors, highly expressed miR-21 is involved in the differentiation, proliferation and apoptosis of the cells, mostly through regulation of the expression of genes related to these processes, therefore playing a part in promoting the genesis and development of tumors \[[@R17], [@R18]\]. Our data showed that 70.4% of the alcohol-using patients had a higher miR-21 expression when compared to the patients who did not drink alcohol (this analysis included all HNSCC tumors). In contrast to this finding, Hu et al. did not find any correlation between alcohol use and the expression level of miR-21 in larynx tumors \[[@R19]\]. MiR-21 was highly expressed in the larynx \[[@R16]\], pharynx \[[@R20]\], tongue \[[@R21]\], tonsils \[[@R22]\] and in HNSCC \[[@R12]\] when compared to healthy tissue as well as in blood from oral squamous cell carcinoma (OSCC) patients when compared to normal healthy blood controls \[[@R17]\]. Nevertheless, these publications did not relate alcohol consumption to miR-21 expression, possibly because of the lack of information or statistical significance. Regarding to treatment response, 66.7% of the patients who did not have a complete response after chemoradiation had a higher expression of miR-21 when compared to the patients who responded. Corroborating our study, Li et al. also found that tongue tumors with advanced clinical stages, poor differentiation or lymph node metastasis expressed higher levels of miR-21, suggesting that miR-21 is related to cancer progression \[[@R23]\].

MiR-494 is located in human chromosome 14q32 and functions as tumor suppressive or oncogenic miRNA, depending on the tumor type \[[@R24], [@R25]\]. Low expression of miR-494 has been reported in prostate cancer \[[@R26]\], lung cancer \[[@R25]\] and gastrointestinal tumors \[[@R24], [@R27]\]. In contrast, miR-494 is up-regulated in colorectal cancer \[[@R24], [@R28]\]. Interestingly, the genomic region where miR-494 is located has been reported as deleted in 40% of HNSCC patients; these tumors exhibited loss of heterozygosity (LOH) of 14q in at least one allele, and this loss was also correlated with a three-fold increased risk of death \[[@R29]\]. Chang et al. found that miR-494 was down-regulated in HNSCC by microarray, but these data could not be validated by RT-qPCR \[[@R20]\]. Libório-Kimura et al. observed a similar down-regulation in a separate study, where oral cancer tumors were compared to normal healthy tissues \[[@R30]\]. In contrast, OSCC patients' blood showed a 2-fold up-regulation of miR-494 when compared to healthy control blood \[[@R31]\]. In regard to our study, we did not found any correlation between miR-494 and clinical-pathological characteristics.

MiR-720, originally annotated as a microRNA, has been reclassified as a transfer RNA fragment (tRF). This recently discovered class of small RNAs has been found to be present in diverse organisms at read counts comparable to miRNAs and there is a debate about their biogenesis and function \[[@R32]--[@R34]\]. Regardless of its origin and function, miR-720 has been described as a circulating serum biomarker in some tumors, such as colorectal cancers and myelomas \[[@R35]--[@R37]\]. MiR-720 expression was significantly up-regulated in cervix squamous cell carcinoma tissue when compared to normal cervix tissue, indicating that miR-720 is closely related to the pathological processes of cervical cancer \[[@R38]\]. Li et al. found that the expression of miR-720 was significantly down-regulated in primary breast cancers, with greater down-regulation in metastatic tumors \[[@R39]\]. Analysis in breast cancers demonstrated that decreased expression of miR-720 was correlated with lymph node metastasis, and re-expression of this miR/tRF in breast cancer cells inhibited cell invasion and migration \[[@R39]\]. Our results showed that 62.9% of the oropharynx patients had a higher miR-720 expression when compared to larynx and hypopharynx patients. To the best of our knowledge, this is the first study that shows a correlation between miR-720 and head and neck cancer.

MiR-923 appears to be a fragment of 28S rRNA. Nevertheless, like miR-720, it has been correlated with survival time. An article comparing bladder cancer patients who received a first-line platinum chemotherapy for locally advanced and/or metastatic carcinoma found that patients with long survival (\> 1 year) had a 1.5-fold increased expression of miR-923 compared with patients with short survival (\< 1 year) \[[@R40]\]. Zhou et al. showed that miR-923 was up-regulated in Taxol-resistant breast cancer cells, when compared to Taxol-sensitive parental cells \[[@R41]\]. MiR-923 was also down-regulated in lymphocytic leukemia cells \[[@R42]\] and receptive endometrium \[[@R43]\]. We could not confirm findings regarding the correlation of miR-923 with prognosis in our study.

MicroRNAs are promising candidates for use as diagnostic markers because they play an important role in many processes involved in tumor metastasis, have tumor and tissue-specific expression, can be evaluated using a sensitive and quick technique and are suitable to be assessed in FFPE tissues and body fluids. This study presents the evaluation of miRNAs as response predictors and points to a correlation between expression of miR-21 and treatment outcome. Moreover, the high expression of miR-21 in this group of samples is associated with a better 5-year overall survival. The results of this study suggest that the evaluation of miR-21 expression could be an important tool for the management of HNSCC patients, assisting in the stratification of patients who may benefit from an organ preservation protocol and contributing to an improvement in quality of life and survival rates.

PATIENTS AND METHODS {#s4}
====================

Population cohort {#s4_1}
-----------------

The present study included a cohort of 71 patients undergoing organ preservation protocol between 2009 and 2011 at the Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil. Patients were eligible if they had a locally advanced tumor (clinical stage III or IVa-b; M0) of the oropharynx, larynx or hypopharynx that was histologically confirmed as squamous cell carcinoma. Patients should not have been previously submitted to any oncological treatment and have a FFPE sample available for molecular analysis. All patients were required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), an ECOG-PS ≤ 2 (Eastern Cooperative Oncology Group Performance Status), an age of at least 18 years and adequate liver, renal and bone marrow function. Exclusion criteria included a history of another malignancy, presence of a serious concomitant illness and a psychiatric illness that would preclude the delivery of the treatment. The study was approved by the Barretos Cancer Hospital Institutional Review Board.

Organ preservation protocol {#s4_2}
---------------------------

The organ preservation protocol was based on a protocol used in a phase II clinical trial carried out in our institution; the details of that study were previously published \[[@R3]\]. In summary, the phase II clinical trial was designed to evaluate the feasibility of delivering cisplatin concurrent with radiotherapy after 3 cycles of an induction chemotherapy regimen based on the combination of cisplatin and paclitaxel in advanced HNSCC patients. Patients were monitored every 3 months during the first 2 years and every 6 months thereafter. Physical examination, radiographic disease assessment (CT/MRI scan of head, neck and chest) and fiberoptic endoscopy of the upper digestive tract were performed during regular monitoring or when disease progression/recurrence was suspected.

FFPE sample processing and RNA purification {#s4_3}
-------------------------------------------

H&E sections corresponding to paraffin blocks containing the samples of interest were reviewed by a pathologist to confirm the diagnosis and to characterize the cellular components present. Selected areas in the FFPE samples containing at least 70% of malignant cells were submitted to a total RNA isolation protocol using the Recover All Total Nucleic Acid Isolation kit (*Life Technologies*). The samples were initially treated with xylene, followed by washing twice with absolute ethanol and proteinase K treatment at 50°C for 3 hours. Quantification was performed using a Qubit fluorometer (*Invitrogen*, Carlsbad, CA, USA). RNA was stored at −80°C until use. Due to the scarcity of RNA obtained from FFPE samples, RNA purity or integrity was not evaluated. The amplification of the internal controls (U6 and RNU48) by RT-qPCR was used as indicative of the high quality of the RNA samples.

miRNA microarrays {#s4_4}
-----------------

The Agilent Human miRNA Microarray (8×15K - G4471A, *Agilent Technologies*) was used in 15 samples from FFPE sections. A total of 100 ng of total RNA was hybridized using miRNA complete labeling and the Hyb Kit (*Agilent Technologies*), according to the manufacturer\'s instructions. The reactions followed a 2-step preparation, represented by dephosphorylation and denaturation of the total RNA followed by incorporation of the Cy3 fluorochrome in a ligation reaction by the T4 ligase. The next steps included standard washing procedures and hybridization with microarray slides. The images were scanned using an Agilent DNA microarray scanner with SureScan technology (*Agilent Technologies*). Raw data were submitted to ArrayExpress (E-MTAB-4854).

The raw data were obtained using Feature Extraction software v.11.0 (Agilent Technologies) and submitted to R environment v. 3.2.3 \[[@R44]\] for further analysis. The median signals (*gMedianSignal* and *gBGMedianSignal*) were used. Following background subtraction and log2 scale transformation, the normalization was performed using the quantile method with the aroma light package \[[@R45]\]. Differentially expressed microRNAs were obtained by rank product analysis using the RankProd package \[[@R46]\], considering p-values and positive false predictions (pfp) ≤ 0.05. Differentially expressed microRNAs were clustered using the Pearson correlation in a ComplexHeatmaps package \[[@R47]\].

RT-qPCR validation of selected differentially expressed miRNAs {#s4_5}
--------------------------------------------------------------

RT-qPCR validation of selected differentially expressed miRNAs was performed in FFPE samples from a different set of 47 patients (not included in the 'screening set'). Each assay was conducted using the Taqman MicroRNA Reverse Transcription kit (*Applied Biosystems*) according to the manufacturer\'s protocol. Briefly, 10 ng of total RNA was reverse-transcribed to cDNA using a MultiScribe Reverse Transcriptase and a stem-loop primer (*Applied Biosystems*) specific for each microRNA, according to manufacturer\'s instructions. RT-qPCR was performed using a TaqMan PCR kit on 96-well plates in the 7900HT Fast Real-Time PCR System (*Applied Biosystems*). All reactions were performed in triplicate. To evaluate the differential expression of each microRNA, the 2-^ΔCt^ method was employed \[[@R47]\]. Mean Ct values of U6 (assay: U6 snRNA 001973) and RNU48 (assay: RNU48 snRNA 001006) were used for normalization. The miRNA levels measured during the validation step were converted into discrete variables by splitting the samples into two classes (high and low expression) using the ΔCt median level and considering all samples were evaluated as cutoff. The expression assay IDs of the miRNA that were analyzed were as follows: hsa-mir-21 snRNA 000397, hsa-mir-923 snRNA 002153, hsa-mir-720 snRNA 002895 and hsa-mir-494 snRNA 002365.

p16 immunoexpression {#s4_6}
--------------------

p16 immunoexpression was assessed by immunohistochemistry (IHC) performed on 4 mm thick formalin-fixed paraffin embedded (FFPE) tissue sections, using the CINtec® p16INK4A assay, according to the manufacturer\'s instructions (CINtec® Histology Kit, Ventana Medical Systems, Inc., Tucson, Arizona, USA). For oropharynx cases only, when p16 staining was observed in ≥ 75% of tumor cells, we would consider the tumor as HPV positive.

Statistical analysis {#s4_7}
--------------------

The Chi square test and Fisher\'s exact test were used to evaluate the associations between miRNA expression, tumor response and clinical variables, as appropriate. A multivariate logistic regression was performed to identify the independent variables associated with tumor response in the organ preservation protocol. The logistic regression model was performed in a step-forward fashion and clinical and molecular variables with a p-value \<0.20 in the univariate analysis were selected to build a final model, which was then further adjusted for important clinical variables.

The Kaplan--Meier method was used to estimate disease-free survival (DFS) and overall survival (OS) of patients, and the log-rank test was used to examine the differences between groups. The DFS was defined as the time interval between the date of the initial treatment and the date of diagnosis of the first recurrence or tumor progression or the last date of follow-up if recurrence or progression was not observed. The OS was defined as the time interval between the date of the initial treatment and the date of death or the last date of follow-up if the patient was alive. Cox proportional hazard regression analysis was performed in a step-forward fashion to estimate the hazard ratios (HR); the multivariate Cox regression model included clinical and molecular variables, which presented a p-value \<0.20 in the univariate analysis and were selected to build a final model. The final model was then further adjusted for clinically important variables. A p-value \<0.05 was necessary to determine statistically significant differences. All statistical analyses were performed using SPSS statistics 23.0.
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